RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy aims to shrink advanced head and neck tumors
Disease control Recruiting nowThis study tests a combination of three treatments—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 adults with advanced head and neck cancer that has returned or spread. The goal is to see if this mix can s…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
Could a single immunotherapy drug replace harsh Chemo-Radiation for head and neck cancer?
Disease control Recruiting nowThis study compares the immunotherapy drug pembrolizumab (Keytruda) against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (positive margi…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Light-Activated drug combo shows promise in fighting head and neck cancer
Disease control Recruiting nowThis study tests a new treatment called ASP-1929 photoimmunotherapy, which uses light to activate a drug that targets cancer cells, combined with the immunotherapy pembrolizumab. It is for people with head and neck cancer that has come back in the same area but has not spread to …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Promising combo therapy for recurrent head and neck cancer enters human trials
Disease control Recruiting nowThis study tests whether combining radiation therapy (either standard X-ray or proton beam) with an immunotherapy drug (pembrolizumab) before surgery is safe and effective for people with recurrent head and neck cancer. About 40 participants will receive the combination treatment…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat head and neck cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer. The cancer has either come back or spread and no longer responds to platinum chemotherapy. About 158 adults will be randomly assigned to …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The goal is to find the safest dose and see if the vaccine helps the immune system …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug duo aims to extend life in tough-to-treat head and neck cancer
Disease control Recruiting nowThis phase 3 study tests whether adding ficlatuzumab to standard cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer or keep their cancer from growing. About 410 adults will receive either the combination or a placebo plus cetuximab. …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug duo aims to shrink head and neck tumors
Disease control Recruiting nowThis study tests whether adding ficerafusp alfa to standard immunotherapy (pembrolizumab) can shrink tumors or extend life in people with advanced head and neck cancer that has spread or come back. About 650 adults with PD-L1-positive cancer will receive either the combination or…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding the cholesterol-lowering drug lovastatin to the immunotherapy pembrolizumab can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS≥1) will receive both drugs.…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for head and neck cancer: drug works after immunotherapy fails
Disease control Recruiting nowThis study tests whether the drug cetuximab can shrink tumors in people with head and neck cancer that has spread or come back, after they have already tried immunotherapy. About 38 adults will receive cetuximab alone. The main goal is to see how many patients' tumors shrink or d…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New combo therapy aims to extend lives in tough cancer recurrence
Disease control Recruiting nowThis study is for adults whose head and neck cancer has returned locally after previous radiation treatment. It compares two approaches: one group gets a repeat course of radiation with chemotherapy followed by immunotherapy (pembrolizumab), while the other gets the standard immu…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Glow-in-the-Dark dye helps surgeons spot hidden cancer cells
Diagnosis Recruiting nowThis early-phase trial tests whether combining two imaging techniques—a radioactive tracer and a fluorescent dye—can help surgeons see and remove head and neck cancer more completely. About 40 adults with head and neck cancer will receive both imaging agents before and during sur…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 16, 2026 23:38 UTC
-
New imaging agent could spot hidden cancer in neck lymph nodes
Diagnosis Recruiting nowThis early-stage trial tests a radioactive drug called 111In-panitumumab to see if it can better find cancer that has spread to lymph nodes in people with head and neck cancer. About 30 adults scheduled for surgery will receive the drug and then get a special scan (SPECT/CT) to s…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated May 04, 2026 16:23 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Symptom relief Recruiting nowThis study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 16, 2026 23:47 UTC
-
Cancer patients may soon get immunotherapy at home – no more long clinic trips!
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated May 16, 2026 23:46 UTC
-
New blood test may predict head and neck cancer outcomes
Knowledge-focused Recruiting nowThis study looks at whether a special blood test can help predict how advanced head and neck cancer will progress. Researchers will collect blood samples from 30 patients with recurrent or metastatic head and neck cancer. They will analyze cancer cells and immune cells in the blo…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated May 16, 2026 23:47 UTC
-
Remote hearing tests could save cancer Patients' hearing
Knowledge-focused Recruiting nowThis study looks at whether offering hearing tests close to home or remotely can help more head and neck cancer patients get their hearing checked during and after treatment. Many patients on cisplatin chemotherapy or radiation may lose hearing, but traveling to the clinic for te…
Matched conditions: RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 11, 2026 20:38 UTC